Quidel (QDEL) Q1 2020 Earnings Call Transcript

Quidel (QDEL)
Q1 2020 Earnings Call
May 06, 2020, 5:00 p.m. ET

Contents:

• Prepared Remarks
• Questions and Answers
• Call Participants

Prepared Remarks:

Operator

Ladies and gentlemen, thank you for standing by. And welcome to the Quidel Corporation first-quarter 2020 earnings conference call. [Operator instructions] I will now turn the call over to Mr. Ruben Argueta, Quidel's director of investor relations.

Please go ahead.

Ruben Argueta -- Director of Investor Relations

Thank you, operator. Good afternoon, everyone, and thank you for joining today's call. With me today is our president and chief executive officer, Doug Bryant; and Randy Steward, our chief financial officer. Our first-quarter 2020 earnings release is now available on ir.quidel.com, our investor relations website.

We will also post our prepared remarks on the presentations tab of our IR website following the conclusion of this call on May 6 for a period of 24 hours. Please note that this conference call will include forward-looking statements within the meaning of federal securities laws. It is possible that actual results and performance could differ significantly from these stated expectations. For a discussion of risk factors, please review Quidel's annual report on Form 10-K, registration statements and subsequent quarterly reports on Form 10-Q as filed with the SEC.

Furthermore, this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, May 6, 2020. Quidel undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call, except as required by law. Today, Quidel released financial results for the three months ended March 31, 2020. If you have not received our news release or if you would like to be added to the company's distribution list, please contact me at 858-646-8023.

Following Doug's comments, Randy will briefly discuss our financial results. Then we'll open the call to take your questions. I'll now hand the call over to Doug for his comments.

Doug Bryant -- President and Chief Executive Officer

Thank you, Ruben, and good afternoon, everyone. First-quarter 2020 feels like a really long time ago. We had a good quarter in terms of product development, manufacturing and financial performance. I will be unusually brief, though, as I know there were -- or there will be several questions with respect to what we are doing with our SARS 2 coronavirus assays.

Total revenue for Q1 was roughly 175 million, driven by 80 million in Influenza testing revenue, which demonstrated the strength of our Sofia franchise and shows what leveraging 43,000 analyzers looks like. Favorability in respiratory disease testing was offset by a decline at the end of the quarter in patient demand for our cardio metabolic products. In terms of product development, first, the Savanna team made significant progress, which gives me a great deal of confidence as we exit this year that we'll have a highly competitive sample to answer molecular platform, one that will likely begin to take significant market share in 2021. I predict that Savanna will become within a two to three-year window our next flagship product, perhaps equal to our Sofia franchise in importance.

Second, the triage high-sensitivity troponin team prepared and submitted our pre-submission package to the FDA in advance of the dialogue we'll have with them shortly in preparation for the U.S. clinical trial later this year. And finally, while several other assay programs remained on track, we began the development of three COVID-19 product offerings. The Lyra reverse transcriptase PCR for high-volume, high-complexity labs; the Sofia SARS antigen assay and the Sofia serology assay.

On March 17, we received emergency use authorization from the FDA for Lyra SARS-CoV-2 and began immediately solidifying our supply chain and ramping up manufacturing. Before the end of the quarter, we were able to manufacture a modest volume of PCR kits, all of which were sold. The Sofia assays are now in the final stages of development. We suggested a summer launch for both assays and are running slightly ahead of that timetable.

In terms of manufacturing in the quarter, our operations group demonstrated the strength of our supply chain and production teams generating record levels of output, when others in the industry were struggling to keep up with demand. The proven scalability of our Sofia cartridge manufacturing lines during this recent influenza epidemic portends well for our ability to meaningfully contribute to improving U.S. public health during the COVID-19 epidemic. Randy?

Randy Steward -- Chief Financial Officer

Thanks, Doug. Good afternoon, everyone. As we reported earlier today, total revenues for the first quarter of 2020 were $174.7 million as compared to $148 million in the first quarter of 2019. This 18% increase in revenue was driven mostly by growth in flu and other respiratory products.

In the first quarter of 2020, Rapid Immunoassay grew 54% over the prior year, while Molecular Diagnostic Solutions grew 45%, and specialized diagnostic solutions grew 19%. Foreign currency impact was minimal at $500,000 in the quarter. For the cardiometabolic immunoassay business, revenue was $53.9 million, an 18% decrease in the first quarter of 2020 or a 17% decrease in constant currency. Of the $53.9 million in cardiometabolic revenue, $28.5 million was derived from the triage business and $25.5 million from the Beckman BNP business.

In the first quarter, we saw an atypical decline in all the major geographies as patients with chest pain either would not or could not visit traditional testing centers as a result of the coronavirus pandemic. We believe this quarter trend will continue for the next couple quarters. Rapid immunoassay product revenues increased 54% to $95.9 million and this compares to $62.5 million in the previous year. Within this category, Sofia products grew 52% from the first quarter of 2019 to $65.2 million while QuickVue product revenues increased 61% to $29.5 million, both driven mostly by Influenza.

Total influenza revenue, which includes rapid immunoassay, DHI and molecular diagnostics grew 69% in the quarter to $79.6 million. The Influenza Rapid Immunoassay revenue was $73.8 million with approximately 76% of the revenue derived from the Sofia platform. Rapid Immunoassay revenue for Strep grew 22% in the quarter, and RSV revenue grew 17%. Revenue in the specialized diagnostic solutions category increased 19% in the first quarter to $16.5 million, driven by a 36% increase in DHI Respiratory revenue and 44% growth in our general virology segment.

Our molecular diagnostic solutions category increased 45% in the quarter to $8.4 million due to a 41% revenue growth in Savanna. This growth was primarily driven by the respiratory season as Influenza revenue grew 120% and Strep A grew 24%. Adding to the overall molecular growth, the Lyra product category grew to $1.7 million in the quarter, driven by $1 million in sales of our Lyra SARS-CoV-2 product, which is granted EUA approval by the FDA on March 17. Gross profit in the first quarter of 2020 increased $24.1 to $115 million, primarily driven by higher sales volumes, favorable product and geographic mix and higher manufacturing overhead absorption.

Gross profit margin in the first quarter of 2020 improved to 65.8%. R&D expense increased by $2.4 million in the first quarter as compared to the same period in 2019. The increase is due to higher employee-related costs, increased spending on clinical trials, development of COVID-19 assays and next-generation platform development projects. Sales and marketing expense in the first quarter increased by $1.1 million as compared to the same period last year due to higher employee-related costs, driven by increased revenue in the quarter.

G&A expenses increased by $900,000 in the quarter, primarily due to greater employee-related costs driven by improved financial performance in the quarter. As it relates to the provision for income taxes, we recorded $8.6 million in income tax provision in the quarter, and the effective tax rate was 17.6%. From the statutory tax rate of 21%, the effective tax rate benefited from foreign-derived intangible income, R&D tax credits and stock-based compensation, somewhat offset by state taxes and other onetime discrete items. As of the end of March, we had $108.8 million in cash and cash equivalents.

In April, we made the third annual payment and now have $136 million principal balance remaining on the deferred and contingent consideration to be paid over the next three years. We have no outstanding debt balance on our $175 million revolving credit facility and only $13 million remaining in convertible bond debt, which matures this December. In short, we have minimal debt, access to credit and good cash flow, which places us in a great position to support our future initiatives. And with that, we conclude our formal comments for today.

Operator, we're now ready to open the call for questions.

Questions & Answers:

Operator

[Operator instructions] Your first question will be from the line of Alex Nowak with Craig-Hallum Capital. Please go ahead.

Alex Nowak -- Craig-Hallum Capital Group -- Analyst

Good afternoon everyone. Doug, can you help us out from a market opportunity here on the COVID Sofia test, have you run any scenarios thinking about what COVID testing could be as a percentage of what you're doing from flu over the next several years? Because I think a lot of people out here are trying to figure out how frequently are you going to be testing for COVID in the post COVID world? Is this going to be a test that runs just this year? Or is this something that's going to be recurring for a longer time period?

Doug Bryant -- President and Chief Executive Officer

It's an interesting question, and I don't have an answer for you. I really can't speculate on what will happen moving forward. I would guess that, we will be doing fairly high-volume testing for some time into next year. Beyond that, will this be a seasonal virus that we see quite often? Will we test for routinely? Will the vaccine have any impact on that? If it's a vaccine like flu, then you could guess that we'll be doing testing just like we do for flu today.

If it's a vaccine that is very, very useful, then perhaps we wouldn't need to test as frequent -- as frequently. So, it's an interesting question. I understand why you're asking it, but I don't really have a good answer for you.

Alex Nowak -- Craig-Hallum Capital Group -- Analyst

Understood. And when you're speaking with distributors today about preparing for the next flu season, what are you hearing from them? Are they stocking up, expecting a ton of flu testing in this next flu season to rule out COVID? Or are they somewhat expecting a light flu season because we're all being told to socially distance and wash your hands, etc.?

Doug Bryant -- President and Chief Executive Officer

We're not really hearing much from distribution in that regard. What we're preparing for is, some level of volume that we saw recently. And in that regard, we're manufacturing pretty significant volumes that we'll keep in inventory in advance of that, recognizing that we will likely take those same manufacturing lines and begin manufacturing both the COVID antigen product as well as the serology assays.

Alex Nowak -- Craig-Hallum Capital Group -- Analyst

OK. Got it. And just last question, if I can. I think this pandemic really highlights the need for point-of-care testing for COVID, but also just a range of diseases, illnesses.

As you're talking with customers today, are you seeing more demand in recent weeks to place a Sofia in a spot, you typically wouldn't see one? I'm thinking the traditional retail clinics, the pharmacies, even the grocery chain centers. Just wanted to know if this is really going to expand the scope in the use case of point-of-care diagnostics going forward?

Doug Bryant -- President and Chief Executive Officer

I think you're right. We have seen evidence of that prior to this, and this is going to accelerate it.

Alex Nowak -- Craig-Hallum Capital Group -- Analyst

OK. Understood. Thank you.

Operator

And you have a question from the line of Brian Weinstein with William Blair. Please go ahead. Your line is open.

Andrew Brackmann -- William Blair and Company -- Analyst

This is Andrew Brackmann on today. Doug, maybe to start off with your commentary on the Sofia antigen and serology assays for COVID-19. Could you maybe provide a little bit more color on some of the key hurdles that are still out there for bringing these to market? Anything you can say on the time line there, a little bit more firmer than summertime when each of these will be made available? And then how should we be thinking about pricing for these tests, both the stand-alone SARS-CoV-2 and potentially combined flu A, B plus SARS-CoV-2 assay?

Doug Bryant -- President and Chief Executive Officer

I'm pretty sure that was more than one question.

Andrew Brackmann -- William Blair and Company -- Analyst

Just trying to keep you on your feet.

Doug Bryant -- President and Chief Executive Officer

I'll start with timing. We are running ahead of what we have suggested before. And I can't be more specific than that other than we are manufacturing product. We do have an intent to -- as a first step to ship about 40,000 tests into the market imminently, in order to do studies that will be useful in demonstrating the performance of this product.

And so, that's the first step. What we intend to do moving forward is then to take on board customers in the traditional professional segment, in particular, those that would help us in addressing testing for hospital, healthcare providers and first responders. And so, we have a number of work streams beyond that. We'll next target pharmacies and schools.

And all those things before we'll get to companies that want to do testing, either themselves or through third parties like occupational health companies. And then there's another category, dentists, ophthalmologists, optometrists and finally the travel industry. So, in terms of timing, I think more about timing in terms of ramping up manufacturing. We will -- as I said, we'll ship initial tranche that we use for tests with key customers, and then we'll be building to a number that is a subset of our total capacity.

In that regard, we currently have capacity to do about 84 million tests per year for all of the Sofia assays. On top of that, we can do another 30 million QuickVue assays. We're also adding a seventh manufacturing line that will give us additional Sofia cautious capacity of another 30 million tests. And right now, the manufacturing plan is to ramp to a number that is more like 50 to 60 million tests that we would allocate for both the antigen product and the serology product.

In other words, we would get to a point within several weeks moving forward from here to the ability to ship something north of 1 million tests a week. So, in terms of timing, I'm more concerned about us ramping up so that we can address immediately what's required to do those healthcare providers and first responders. And then there's a whole series of things that we want to get to moving forward. But the most important element of all that, the biggest challenge is securing and locking down supply chain and ramping up manufacturing.

So, that's where we're at. I can't be more explicit than that. I don't think, Andrew.

Andrew Brackmann -- William Blair and Company -- Analyst

That's perfect. Anything that you could say, though, on pricing for these assets?

Doug Bryant -- President and Chief Executive Officer

We've determined the price. We'll launch the COVID antigen assay first at a price per test that takes into consideration our increased cost of labor and raw materials for both assays and instruments. We're, of course, looking at what our opportunity costs have been because we've moved people on other projects over to these projects. We'll look at the performance of the product relative to other point-of-care assay products that are currently in market and other factors.

And then our price will become well-known since we start selling it. I'll go home and model it.

Andrew Brackmann -- William Blair and Company -- Analyst

I completely understand. But appreciate that color. And then just sort of last 1 for me. There seems to be a pretty large opportunity to deploy Virena here to track COVID, when to launch these tests? Any details you can provide on how we should be thinking about the business model for that capability moving forward?

Doug Bryant -- President and Chief Executive Officer

Well, we've restated the CDC through our context here and may make adjustments to allow for additional data that they say needs to be collected. I think that will increase the value of that information we provide, which will then provide significant value to our overall product offering, which will help with placements and secure our Sofia franchise. I think it will be an added value that others are going to struggle to mimic. I know there's a lot of expectation around whether we should be charging folks for data, and is there a means of monetizing what we've done? And I would just say that at this time, we want to do the best for public health that we can.

And right now, we don't have an intent to charge for data that's collected. We will provide that to the CDC, to state, county and city public health departments as they require, and we'll do that at no charge. The benefit to us from a monetary perspective would obviously be that we would hope to be a preferred supplier of these types of products. And that's -- I think that's how we'll recoup the investment we've made there.

I do recognize that a lot of people are saying, boy, those data are valuable. Is there a way that you can monetize that? And maybe there is moving forward. But right now, I just don't feel like that's the right thing for us to do.

Andrew Brackmann -- William Blair and Company -- Analyst

I got you. Thanks, guys.

Doug Bryant -- President and Chief Executive Officer

Thanks, Andrew.

Operator

Your next question will be from the line of Tycho Peterson with JP Morgan. Please go ahead.

Tycho Peterson -- J.P. Morgan -- Analyst

Hey, good afternoon. Doug, can you talk a little bit about Lyra? You did $1 million? You said you still have all the PCR kits you can manufacture. You're now doing kind of 500,000 tests per week. How do you think about the trajectory of that going forward?

Doug Bryant -- President and Chief Executive Officer

Yeah. What an exercise that was for us, we'll admit it. The bill of materials on these assays is long, and there's a lot of components, and we struggled at the outset to secure our supply chain. So, we only made a handful of assays in March.

We made, I think, 130,000 tests. The first million got sold in March, and then the remainder of those kits were sold early April. And then we ramped to about 1.5 million tests that we did in April, and we're going to be moving forward at effectively 1,000 kits a day, which is 480,000 tests per week. Some folks are going to say, well, can you manufacture Saturday, Sunday? My answer there would be, we are, but we're manufacturing our other stuff on Saturdays and Sundays.

So, I suppose we could make more if we had to. But 480,000 tests is where we're at now, and it's pretty solid. Early on, we had trouble getting probes and primers. Our principal supplier of enzymes said they forgot our order.

We had to lock down all sorts of chemicals and components of this process. The guys in Ohio that are manufacturing this product did a tremendous job for us. We're now solid at 1,000 kits a day, 480,000 tests a week. As we exit June in the last week, our forecast, which is put together by customer basis has just roughly two-thirds of our manufacturing capacity.

So, we think by the end of June, we'll have a run rate for shipping on a weekly basis that would be roughly two-thirds of that 480,000 tests that we would have manufactured that week. So, that's what we think we're going to be. I like the fact that we'll have a little bit of inventory. That was a concern of ours.

We didn't want start-up customers that we couldn't supply routinely and sustainably. So, that's kind of where we're at. It's been a great experience for us. A lot of people, I think, were surprised that we could do all this in short order.

But we've got a great team in terms of scientific count, but also in terms of our supply chain and our operations guide. So, a nice little additional business that we've added on to our overall infrastructure.

Tycho Peterson -- J.P. Morgan -- Analyst

And then as we think about Sofia, I appreciate you don't want to talk explicitly about pricing. But if we think about flu pricing, is there any reason it should be materially different from the antigen test? I think you get about $10 to your distributors on this weekly?

Doug Bryant -- President and Chief Executive Officer

It will be higher. And the volumes will be dramatically higher.

Tycho Peterson -- J.P. Morgan -- Analyst

And maybe lastly, I mean I know you had the question before about how you think about the market evolving, but you've got the manufacturer, Roche and Hologic scaling up, you've got the syndromic players. How do you think about how much of this market ends up getting centralized versus decentralized? And can you talk a little bit about how you see the Sofia test stacking up versus some of the syndromic panels that COVID will be added to?

Doug Bryant -- President and Chief Executive Officer

This market will become extraordinarily democratized. And if you just follow the flu example, more than 90% of flu tests are done by rapid tests because they can't be done by molecular methods. And I do respect what the molecular players are doing in trying to increase their capacity. And I'm glad they're doing it.

But at the end of the day, the constraint on the molecular side is more in the lab than it is on the manufacturers. So, I think it will be beneficial to public health that these large Panther systems, not just the Panther Fusion, can run the assays, and I'm appreciative of what that company is doing. But at the end of the day, if we're going to be doing 1 million tests a day, we can't get there by molecular methods. And so, it's going to be useful not only that I enter the market with the volume that we're talking about.

But we need BD, we need Abbott, we need Roche, we need all of the players to be developing rapid antigen tests and rapid serology tests as well. Otherwise, we're not going to get everybody tested. And meaningfully -- in a meaningful number that will be useful to get people back to work. So, this is a huge task.

But it's not just on the IVD manufacturers. It's also on the people who have to run it. People who have to do the swabbing, accessioning the samples, getting the samples to where they need to be. And there's extreme value in being able to test on the spot and not have to wait.

I know for my own company, that I'm thankful that we're going to be able to test everybody under 15 minutes, and we'll be able to tell them whether they can enter the building and stay working.

Tycho Peterson -- J.P. Morgan -- Analyst

Lastly, just anything you can say on specificity or sensitivity for the serology test. Obviously, there have been press reports about mixed quality of the test that were brought to market earlier. I assume your quality is going to be much higher, but any numbers you can give us on performance?

Doug Bryant -- President and Chief Executive Officer

Sure. Let me talk about antigen first. What we've done, which is what all of the rapid antigen folks will have to do is you'll have to look at samples that you know are positive by PCR for patients. And then you'll need to run those tests as you have the samples against your own product.

And when we do that, even in that diluted format, which is not how we would do the test in the field, even at that diluted sample, we are of a sensitivity that meets the hurdle required and exceeds actually noticeably what the FDA would expect. Once we actually run those samples clinically on patients in the field on dry swabs, we expect an improvement of LOD of about eightfold. And so, we will see an assay with Sofia that effectively is equivalent to an isothermal methodology, even though it's molecular, but still short of what PCR tests are. In terms of specificity, the specificity there will be quite high as we go into the markets there.

This is also why we're focused early on in getting 40,000 tests or so out there, so we can run a lot of actual patient samples in order to give people confidence that this product is as good as what you see out there today. On the serology side, I have a lot of concerns about serology because even if I manufacture a product that's 99% specific and 90% sensitive, which I think most of us are going to be able to do, the positive predictive value is really unknown. I don't know what the prevalence out there is. So, if the prevalence is only 1%, I know you know how to do the math on positive predictive value.

But if you take on 1,000 samples, with 90% sensitivity, 99% specificity, I'm dividing nine by 19 and coming up with 47%, which is less than a coin flip on a positive sample that you're going to test for. Now if we're at 10%, then the math changes, is now about 91%. So, the test may be put together very well, and we may be able to demonstrate in our hands that we're highly specific and highly sensitive. But if the prevalence is low, there's going to be a time that these tests are not going to be as useful.

So, I see a world where we're going to be doing both for a while. We're going to be doing antigen, and we're going to be doing serology. Now there is a benefit of having a serology of actually determining what the prevalence is. But it's going to be some time before we actually understand what that prevalence is.

So, as I look at it, I'm more concerned about what the prevalence is, not the performance of our assay and the other assays that I see that are out there. Now you did refer to assays that weren't validated and I'm not even going to comment on that. I think that was a mistake to allow assays to be imported into the United States that have not been validated. And I really don't want to speak more about that.

Tycho Peterson -- J.P. Morgan -- Analyst

Understood. Thanks for the color.

Operator

[Operator instructions] Your next question will come from the line of Andrew Cooper with Raymond James. Please go ahead.

Andrew Cooper -- Raymond James -- Analyst

Hey. A lot's already been asked. But I guess, just kind of 1 piece, looking maybe a little bit beyond just COVID-19. As we think about flu, obviously, I think there was a lift as early on in the process, you were looking to rule out anything that could have looked like COVID-19 and that sort of changed as things progress.

So, are your flu volumes still elevated because of the coronavirus pandemic? Or have those sort of started to tail off more like the typical seasonality that you might see in May?

Doug Bryant -- President and Chief Executive Officer

They have tailed off, Andrew. I will say that the beginning of second quarter was reasonably strong. So, if you take our typical second quarter and you're trying to model, you probably are branching that up just a bit. But it has now tailed off.

And we're not seeing anything in May of significance.

Andrew Cooper -- Raymond James -- Analyst

OK. That's helpful. And I guess, maybe jumping into the COVID kind of discussions. In terms of Sofia, and you talked about potentially some incremental demand at other avenues of care.

What's your capacity from an instrument perspective if you get this test launched at the time line you expect and your -- as far as we know, the first -- kind of first rapid antigen with any scale coming to market, what's your ability to ramp that 43,000 to something higher by whether it's end of the year? Just sort of how you think about that trajectory?

Doug Bryant -- President and Chief Executive Officer

Yeah. Instruments active in the U.S. right now to be very accurate are right at 36,000. We have on hand something approaching 5,000.

And then we've got 1,000 that are being built right now. Our monthly normal manufacturing would be at about 1,000 moving forward, but we've also added another party that's helping us out, and we hope to ramp to about 7,000 analyzers a month beginning in September. So, we firmly believe that the number of analyzers, given all those work streams that I talked about are going to be necessary. And we're going about as fast as we can to make sure we have all those analyzers out there before -- certainly before the fourth quarter.

Andrew Cooper -- Raymond James -- Analyst

OK. Great. That's really helpful. And then maybe a little bit longer term, as you think about sort of those dynamics and there's players out there talking about home-based testing.

And I think with what you can do with Sofia 3 or Sniffles is kind of -- has that changed the way you think about that product and how it could be used and deployed out into kind of the real world? Or any comment around that would be of interest?

Doug Bryant -- President and Chief Executive Officer

We always thought that a combination of telehealth and what we're doing with Sniffles makes sense. This experiences is just confirming that or causing us to think, boy, we got to go faster here. The number of patients that are now enrolled in telehealth increased dramatically in the first quarter. And so, I think moving forward, it's going to be increasingly an access point to healthcare.

So, I love the fact that we've got the product in development. It's on schedule for year-end. We are thinking through how we partner with others to make this happen. I'm staying away from the at-home testing so much because I don't know what the tolerance will be for this particular virus in terms of how the FDA thinks about testing at-home.

But certainly, under the care of a physician through telehealth, I think Sniffels is going to be important. I guess that was -- is there another question?

Operator

He is not in the queue any longer.

Doug Bryant -- President and Chief Executive Officer

OK. Perfect. Perfect. OK.

Perfect. Well, before I say thanks, everyone, and see you later and all that, I will mention that this has really been an interesting start to the year. We certainly have to have changed direction and all that. But at the same time, we have stayed focused on the things that we've been working on.

In particular, I have to say that if it weren't for the COVID discussion, I would be spending a lot of time right now talking about Savanna. We are now more convinced that we're going to do well with this product. We've made significant progress over the last several months. Our thermal recycling times now are down to 10 seconds per cycle.

We think that we can do a reverse transcriptase assay, our RVP, respiratory viral panel, which more than likely will include COVID-19. We think we can do in 18 minutes TAT. We're working on actually decreasing that. And for DNA assay, those panels, we think we can get that down to 13 minutes.

So, isothermal speed and footprint with Savanna, but with PCR performance. And we think that we're going to make significant progress with our molecular franchise once we introduce Savanna in 2021. So, if it weren't for this other distraction, we would be spending a lot of time talking about that because I really do think that that's our next franchise. That's our next flagship product.

So, with that, I'll say thanks for everyone for your support and your interest in our company. We did have a strong start to the year. And we're in really good shape to achieve our objectives over the next few years. Thanks again.

Operator

[Operator signoff]

Duration: 40 minutes

Call participants:

Ruben Argueta -- Director of Investor Relations

Doug Bryant -- President and Chief Executive Officer

Randy Steward -- Chief Financial Officer

Alex Nowak -- Craig-Hallum Capital Group -- Analyst

Andrew Brackmann -- William Blair and Company -- Analyst

Tycho Peterson -- J.P. Morgan -- Analyst

Andrew Cooper -- Raymond James -- Analyst

More QDEL analysis

All earnings call transcripts